Cannabidiol — Discount Pricing
Cannabidiol is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Cannabidiol Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $168.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Cannabidiol
Cannabidiol is a prescription medication. Ask your doctor if Cannabidiol is right for you.
How to Check Cannabidiol Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Cannabidiol at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Neurological
About Cannabidiol
Cannabidiol, commonly known as CBD, is a prescription medication derived from cannabis that's primarily used to treat certain types of seizures and other conditions. While CBD has gained popularity in wellness circles, the FDA-approved pharmaceutical version offers proven therapeutic benefits. TheDrugClub members can access their prescribed cannabidiol medications with $0 co-pays and free home delivery, making treatment more affordable and convenient.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Cannabidiol is approved for (FDA label)
EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: May 29, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Cannabidiol (FDA label)
Cannabidiol oral solution: 100 mg/mL of a strawberry-flavored, clear, colorless to yellow solution. Oral solution: 100 mg/mL ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 8bf27097-4870-43fb-94f0-f3d0871d1eec. SPL document ID: 1eb7ac65-8df5-4a4a-9156-802cfaa92b06. Label effective date: May 29, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Cannabidiol (FDA label)
The following important adverse reactions are described elsewhere in labeling: • Hepatic Injury [see Warnings and Precautions ( 5.1 )] • Somnolence and Sedation [see Warnings and Precautions ( 5.2 )] • Suicidal Behavior and Ideation [see Warnings and Precautions ( 5.3 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 )] • Withdrawal of Antiepileptic Drugs [see Warnings and Precautions ( 5.5 )] The most common adverse reactions (10% or more for EPIDIOLEX and greater than placebo) in patients with Lennox-Gastaut syndrome or Dravet syndrome are: somnolence; decreased appetite; diarrhea; transaminase elevations; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder, and poor quality sleep; and infections. ( 6.1 ) The most common adverse reactions (10% or more for EPIDIOLEX and greater than placebo) in patients with tuberous sclerosis complex are: diarrhea; transaminase elevations; decreased appetite; somnolence; pyrexia; and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals, Inc. at 1-800-520-5568 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 8bf27097-4870-43fb-94f0-f3d0871d1eec. SPL document ID: 1eb7ac65-8df5-4a4a-9156-802cfaa92b06. Label effective date: May 29, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.